top of page

ASCO 2026: Celcuity CEO Brian Sullivan discusses the late breaking data for the PAM inhibitor gedatolisib that was just presented at ASCO - doubled the likelihood of survival in HR+/HER2- breast

  • 4 hours ago
  • 1 min read

These data were for patients with the PIK3CA mutation. The median PFS for the gedatolisib triplet combo was 11.1 months versus 5.6 months, compared to alpelisib plus fulvestrant.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page